Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

797 ARTÍCULOS , VIENDO DEL 151 AL 165

Mitophagy in Alzheimer's disease and other metabolic disorders: A focus on mitochondrial-targeted therapeutics

Skawratananond S, Xiong DX, Zhang C, Tonk S, Pinili A, Delacruz B, Pham P, Smith SC, Navab R, Reddy PH.

Ageing Res Rev. 2025 Jun;108:102732. doi: 10.1016/j.arr.2025.102732. Epub 2025 Mar 22.

HDAC3 as an Emerging Therapeutic Target for Alzheimer's Disease and other Neurological Disorders

Li Y, Izhar T, Kanekiyo T.

Mol Neurobiol. 2025 Aug;62(8):9573-9585. doi: 10.1007/s12035-025-04866-w. Epub 2025 Mar 24.

Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer's disease: a comprehensive review of the characteristics and therapeutic strategies

Nam Y, Shin SJ, Kumar V, Won J, Kim S, Moon M.

Transl Neurodegener. 2025 Mar 26;14(1):15. doi: 10.1186/s40035-025-00479-4.

Targeting amyloidogenic proteins through cyclic peptides - A medicinal chemistry perspective

Zargaham MK, Ibrahim A, Ahmed M, Babar MM, Rajadas J.

Bioorg Med Chem. 2025 Jun 1;123:118165. doi: 10.1016/j.bmc.2025.118165. Epub 2025 Mar 19.

A review: From old drugs to new solutions: The role of repositioning in alzheimer's disease treatment

Shah FA, Qadir H, Khan JZ, Faheem M.

Neuroscience. 2025 Jun 7;576:167-181. doi: 10.1016/j.neuroscience.2025.03.064. Epub 2025 Mar 29.

Serotonergic Modulators in Alzheimer's Disease: A Hope in the Hopeless Condition

Almohmadi NH, Al-Kuraishy HM, Al-Gareeb AI, Albuhadily AK, Fakhry MM, Alexiou A, Papadakis M, Batiha GE.

Chem Biodivers. 2025 Aug;22(8):e202403401. doi: 10.1002/cbdv.202403401. Epub 2025 Jun 3.

Multi-target approach to Alzheimer's disease prevention and treatment: antioxidant, anti-inflammatory, and amyloid- modulating mechanisms

Abbas K, Mustafa M, Alam M, Habib S, Ahmad W, Adnan M, Hassan MI, Usmani N.

Neurogenetics. 2025 Apr 1;26(1):39. doi: 10.1007/s10048-025-00821-y.

Implication of Central β(2) Adrenergic Receptor for the Development of Novel Drugs Against Alzheimer's Disease

Wang A, Since M, Dallemagne P, Rochais C.

Arch Pharm (Weinheim). 2025 Apr;358(4):e2400750. doi: 10.1002/ardp.202400750.

Harnessing marine resources for Alzheimer's therapy: A review integrating bioactivity and molecular docking

Khalid H, Mohamed H, Eltoukhy A, Saeed MT, Song Y.

Eur J Pharmacol. 2025 Jun 15;997:177611. doi: 10.1016/j.ejphar.2025.177611. Epub 2025 Apr 9.

Potential Benefits of Quercetin through P2X7 Modulation against Neuroinflammation in Alzheimer's Disease

Bianchini MC, Franscescon F, Soares AA, Ansolin V, Pretto KP, da Cunha MLV, de Resende E Silva DT.

Curr Neuropharmacol. 2025;23(11):1367-1379. doi: 10.2174/011570159X355614250130100132.

Photodynamic and Photothermal Therapies using Nanotechnology Approach in Alzheimer's Disease

Ozturk B, Demir H, Gunay MS, Akdag Y, Sahin S, Gulsun T.

Curr Neuropharmacol. 2025;23(14):1985-2003. doi: 10.2174/011570159X370790250317045223.

Past, present, and future of serotonin-targeting therapeutics for Alzheimer's disease: Perspectives from DNA methylation

Liu Y, Aquili L, Wong KH, Lu Z, Lim LW.

Ageing Res Rev. 2025 Jun;108:102755. doi: 10.1016/j.arr.2025.102755. Epub 2025 Apr 14.

Impact of corticoid receptors on Alzheimer's disease: a neuroendocrine perspective

Goel F, Kumar D, Sharma A.

Inflammopharmacology. 2025 May;33(5):2641-2656. doi: 10.1007/s10787-025-01734-w. Epub 2025 Apr 18.

NLRP3 inflammasome in Alzheimer's disease: molecular mechanisms and emerging therapies

Li Z, Gong C.

Front Immunol. 2025 Apr 7;16:1583886. doi: 10.3389/fimmu.2025.1583886. eCollection 2025.

Small molecule-mediated therapeutic approaches to target Tau and Alzheimer's disease

Chinnathambi S.

Adv Protein Chem Struct Biol. 2025;145:287-304. doi: 10.1016/bs.apcsb.2024.11.010. Epub 2024 Dec 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias